Shares of Eli Lilly & Co. LLY sank 0.24% to $772.00 Tuesday, on what proved to be an all-around poor trading session for the stock market, with the S&P 500 Index SPX falling 0.43% to 5,881.63 and Dow ...
Eli Lilly and Company (NYSE:LLY – Get Free Report) was down 0.2% on Thursday . The company traded as low as $791.50 and last ...
Eli Lilly and Company (NYSE:LLY – Get Free Report) was downgraded by research analysts at StockNews.com from a “buy” rating ...
Eli Lilly has been riding the weight-loss drug wave. The company's weight-loss drugs have been shown to be more effective than rival Ozempic. The stock currently trades at an attractive valuation.
On Dec. 9, healthcare giant Eli Lilly announced the approval of a new $15 billion share buyback program and yet another significant dividend increase. For a seventh consecutive year, the company ...
17don MSN
We recently compiled a list of the 16 Best Income Stocks To Buy According to Analysts. In this article, we are going to take ...
Current share price of US$783 suggests Eli Lilly is potentially 41% undervalued Our fair value estimate is 34% higher than Eli Lilly's analyst price target of US$984 Today we'll do a simple run ...
Stocks rally after inflation data but close lower for the week December 21, 2024 The U.S. Food and Drug Administration on Friday approved Eli Lilly's weight-loss treatment, Zepbound, for ...
The United States Food and Drug Administration says the shortage of Eli Lilly’s Zepbound and Mounjaro drugs has been resolved and that specialty pharmacies and online companies need to stop ...
In a study, people who took Zepbound had fewer breathing interruptions. The FDA has expanded the approval of Eli Lilly’s obesity medication Zepbound to include treating moderate to severe ...
This year's developments in the obesity market have really gone in Eli Lilly’s (NYSE:LLY) favor. Clinical trial results from competitors were largely underwhelming, including this week’s ...
The FDA has expanded the approval of Eli Lilly's obesity medication Zepbound to include treating moderate to severe ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback